RX
RxSight, Inc.
RXST · NASDAQ
$6.11 +1.58% (+$0.10)
1M -5.71%
Market Cap $252.7M
P/E Ratio -
Div. Yield -
ROE 17.35%
Bulios Fair Price
$3.61
40.9% downside
Current Price
$6.11
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RXST is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
88 /100
Cheap P/S 1.98x
P/B 0.96x
P/E N/A
Growth
100 /100
Growing Rev. growth 40.00%
Book val. growth 45.28%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 77.50%
Net margin 36.80%
Op. margin 43.20%
Quality
5 /100
Poor ROIC 20.17%
ROE 17.35%
ROA 13.31%
Debt
69 /100
Low Debt/Equity 0.04x
Current ratio 4.07x
Int. coverage -3,121.60x
Stability
30 /100
Unstable Beta 1.16x
Rev. volatility 44.10%
EPS volatility 46.01%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RXST
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Aziz Mottiwala
Employees
461
Headquarters
Aliso Viejo
Upcoming events
04 NOV
Earnings
Upcoming earnings report